CHEK2 and cancer: The CNAs observed this cancer are comparable to other early stage HGS ovarian carcinomas with TP53 mutations and HR defects, suggesting the possibility that PRIM2 and CHEK2 loss in Patient H may contribute to comparable levels of structural alterations.